Questions? Call 800-624-6242 About | Ordering | New Menu | Items in cart [0] SEARCH

PAPERBACK price:$34.50 add to cart Rights & Permissions Free PDF Access Sign in to download PDF book and chapters Free Resources PDF SUMMARY Display this book on your site! Related Titles The Small Business Innovation Research Program: An Assessment of the Department of Defense Fast Track Initiative An Assessment of the SBIR Program Other Related Titles Venture Funding and the NIH SBIR Program (2009) National Research Council (NRC) Citation Manager Export the bibliographic data for this book in your chosen format Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Citation Manager . "Appendix C: NIH List of Firms Excluded on the Grounds of Venture Capital Ownership." Venture Funding and the NIH SBIR Program. Washington, DC: The National Academies Press, 2009. Please select a format: Page 80   E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Appendix C NIH List of Firms Excluded on the Grounds of Venture Capital Ownership* FIRM NAME Altus Biologics, Inc. Applied Genetic Technologies Corp. Arginox Pharmaceuticals Argolyn Bioscience, Inc. Arizeke Pharmaceuticals Ascenta Therapeutics, Inc. Aspect Medical Systems, Inc. Biospect Inc./Predicant Biosciences BrainCells, Inc. Calypso Medical Technologies, Inc. Cell Biosciences Cengent Therapeutics, Inc. CEPTYR, Inc. Cerus Corporation Chlorogen CUMBRE, Inc. Diversa Corp. Encysive Pharmaceuticals FivePrime Therapeutics GlycoFi, Inc. Gryphon Therapeutics, Inc. * These firms were submitted by NIH as an illustrative list of firms they believe were excluded. Page 80 Front Matter (R1-R14) Executive Summary (1-4) 1 Introduction (5-21) 2 Study Methodology (22-29) 3 Venture Funding for NIH Phase II Winners, 1992-2002 (30-38) 4 Focus on the Top 200 Award Winners (39-42) 5 Other Sources of Data on the Participation of Venture-owned Firms (43-48) 6 Comparing Project Outcomes (49-60) 7 Impact of the SBA Ruling on the NIH SBIR Program (61-68) Appendixes (69-70) Appendix A: Venture-funded Firms Among the 200 Most Prolific Winners of NIH Phase II Awards 1992-2002 (71-75) Appendix B: NRC Non-participant Survey (76-79) Appendix C: NIH List of Firms Excluded on the Grounds of Venture Capital Ownership (80-81) Appendix D: Venture-funded Firms: Data from Hoover's Small Business Database and VentureSource (82-91) Appendix E: Analysis of the Evidence Submitted by BIO (92-94) Appendix F: SBA Administrative Ruling on Appeal of Cognetix, Inc. (95-102) Appendix G: Letter from Elias A. Zerhouni, Director, National Institutes of Health to Hector V. Barreto, Administrator, U.S. Small Business Administration, June 28, 2005 (103-106) Appendix H: Testimony by Steven C. Preston, SBA Administrator, to the House Small Business Committee, March 13, 2008 (107-111) Appendix I: Bibliography (112-126)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 80
Venture Funding and the NIH SBIR Program Appendix C NIH List of Firms Excluded on the Grounds of Venture Capital Ownership* FIRM NAME Altus Biologics, Inc. Applied Genetic Technologies Corp. Arginox Pharmaceuticals Argolyn Bioscience, Inc. Arizeke Pharmaceuticals Ascenta Therapeutics, Inc. Aspect Medical Systems, Inc. Biospect Inc./Predicant Biosciences BrainCells, Inc. Calypso Medical Technologies, Inc. Cell Biosciences Cengent Therapeutics, Inc. CEPTYR, Inc. Cerus Corporation Chlorogen CUMBRE, Inc. Diversa Corp. Encysive Pharmaceuticals FivePrime Therapeutics GlycoFi, Inc. Gryphon Therapeutics, Inc. * These firms were submitted by NIH as an illustrative list of firms they believe were excluded.

OCR for page 81
Venture Funding and the NIH SBIR Program Handylab Inc. IDM Pharma, Inc. Infigen, Inc. Inotek Pharmaceuticals Lincoln Technologies Macrogenics, Inc. MEMX Metabolon, Inc. MicroOptical Corporation MicroOptical Engineering Corporation Myomatrix Therapeutics NanoMix, Inc. NanoString Technologies, Inc. Natus Medical (BioLogics) Nephros Therapeutics, Inc. Neurogenetics, Inc. Norak Biosciences, Inc. Northwest Medical Physics Equipment Paratek Pharmaceuticals Peptx, Inc. Phenomix Corp. PTC Therapeutics, Inc. Saegis Pharmaceuticals Inc. Sentrx Surgical/Carbylan Biosurgery Sirtris Pharmaceuticals Threshold Pharmaceuticals, Inc. Transave, Inc. Traxtal, Inc. Trellis Bioscience Tularik, Inc. Vion Pharmaceuticals, Inc. Virxsys Corp. VisEn Medical, Inc. Yasoo Health, Inc.